+

WO2009053535A3 - Vaccin peptidique contre le virus de la grippe - Google Patents

Vaccin peptidique contre le virus de la grippe Download PDF

Info

Publication number
WO2009053535A3
WO2009053535A3 PCT/FI2008/050598 FI2008050598W WO2009053535A3 WO 2009053535 A3 WO2009053535 A3 WO 2009053535A3 FI 2008050598 W FI2008050598 W FI 2008050598W WO 2009053535 A3 WO2009053535 A3 WO 2009053535A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
influenza virus
hemagglutinin
influenza
peptide vaccine
Prior art date
Application number
PCT/FI2008/050598
Other languages
English (en)
Other versions
WO2009053535A2 (fr
Inventor
Jari Natunen
Jukka Hiltunen
Ritva Niemelae
Jari Helin
Olli Aitio
Original Assignee
Glykos Finland Oy
Jari Natunen
Jukka Hiltunen
Ritva Niemelae
Jari Helin
Olli Aitio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/FI2007/050577 external-priority patent/WO2008049974A2/fr
Application filed by Glykos Finland Oy, Jari Natunen, Jukka Hiltunen, Ritva Niemelae, Jari Helin, Olli Aitio filed Critical Glykos Finland Oy
Priority to US12/739,796 priority Critical patent/US20110191867A1/en
Priority to AU2008316397A priority patent/AU2008316397A1/en
Priority to EP08841911A priority patent/EP2296688A2/fr
Publication of WO2009053535A2 publication Critical patent/WO2009053535A2/fr
Priority to PCT/FI2009/050357 priority patent/WO2009133249A1/fr
Publication of WO2009053535A3 publication Critical patent/WO2009053535A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des épitopes peptidiques destinés à être utilisés dans la prévention et/ou le traitement de la grippe ou dans le développement d'un tel traitement ou vaccin contre la grippe. Elle concerne également le procédé d'évaluation du potentiel de liaison d'une structure chimique, telle qu'un anticorps, à un épitope peptidique dérivé du site de liaison aux sialosides divalents de la protéine hémagglutinine du virus de la grippe.
PCT/FI2008/050598 2006-10-26 2008-10-24 Vaccin peptidique contre le virus de la grippe WO2009053535A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/739,796 US20110191867A1 (en) 2006-10-26 2008-10-24 Peptide vaccine for influenza virus
AU2008316397A AU2008316397A1 (en) 2006-10-26 2008-10-24 Peptide vaccine for influenza virus
EP08841911A EP2296688A2 (fr) 2007-10-26 2008-10-24 Vaccin peptidique contre le virus de la grippe
PCT/FI2009/050357 WO2009133249A1 (fr) 2008-05-02 2009-05-04 Vaccin peptidique dirigé contre le virus de la grippe

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/FI2007/050577 WO2008049974A2 (fr) 2006-10-26 2007-10-26 Vaccin peptidique contre le virus de la grippe
FIPCT/FI2007/050577 2007-10-26

Publications (2)

Publication Number Publication Date
WO2009053535A2 WO2009053535A2 (fr) 2009-04-30
WO2009053535A3 true WO2009053535A3 (fr) 2009-07-23

Family

ID=40585511

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2008/050598 WO2009053535A2 (fr) 2006-10-26 2008-10-24 Vaccin peptidique contre le virus de la grippe

Country Status (2)

Country Link
EP (1) EP2296688A2 (fr)
WO (1) WO2009053535A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658180B2 (en) 2008-08-15 2014-02-25 Mark A. Miller Vaccines against influenza virus
EP2684572B1 (fr) * 2011-03-11 2019-05-22 KM Biologics Co., Ltd. Composition d'adjuvant contenant de la citrulline

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998059244A1 (fr) * 1997-06-20 1998-12-30 Eclagen Limited Identification de peptides se liant a des molecules mhc
US20020183484A1 (en) * 1998-10-09 2002-12-05 Torres Jose V. Immunogenic formulation and process for preparation thereof
WO2005037187A2 (fr) * 2003-10-20 2005-04-28 Glykos Finland Oy Ligands de haute affinite pour le virus de la grippe et methodes de production
WO2006111616A1 (fr) * 2005-04-20 2006-10-26 Glykos Finland Oy Vaccin peptidique contre la grippe
WO2006128294A1 (fr) * 2005-06-01 2006-12-07 Variation Biotechnologies Inc. Formulation peptidique de vaccin antigrippal
WO2007122388A2 (fr) * 2006-04-13 2007-11-01 Midatech Limited Nanoparticules destinées à induire des réponses immunitaires contre des agents infectieux
WO2008039267A2 (fr) * 2006-07-21 2008-04-03 Pharmexa Inc. Induction de réponses immunes cellulaires au virus de la grippe grâce à des compositions de peptides et d'acides nucléiques
WO2008049974A2 (fr) * 2006-10-26 2008-05-02 Glykos Finland Oy Vaccin peptidique contre le virus de la grippe
WO2008138120A1 (fr) * 2007-05-11 2008-11-20 University Of Manitoba Système de vecteur lentiviral pseudotypé de l'hémagglutinine h5n1 du virus de la grippe aviaire pour une identification rapide d'antiviraux et une neutralisation de polypeptides

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998059244A1 (fr) * 1997-06-20 1998-12-30 Eclagen Limited Identification de peptides se liant a des molecules mhc
US20020183484A1 (en) * 1998-10-09 2002-12-05 Torres Jose V. Immunogenic formulation and process for preparation thereof
WO2005037187A2 (fr) * 2003-10-20 2005-04-28 Glykos Finland Oy Ligands de haute affinite pour le virus de la grippe et methodes de production
WO2006111616A1 (fr) * 2005-04-20 2006-10-26 Glykos Finland Oy Vaccin peptidique contre la grippe
WO2006128294A1 (fr) * 2005-06-01 2006-12-07 Variation Biotechnologies Inc. Formulation peptidique de vaccin antigrippal
WO2007122388A2 (fr) * 2006-04-13 2007-11-01 Midatech Limited Nanoparticules destinées à induire des réponses immunitaires contre des agents infectieux
WO2008039267A2 (fr) * 2006-07-21 2008-04-03 Pharmexa Inc. Induction de réponses immunes cellulaires au virus de la grippe grâce à des compositions de peptides et d'acides nucléiques
WO2008049974A2 (fr) * 2006-10-26 2008-05-02 Glykos Finland Oy Vaccin peptidique contre le virus de la grippe
WO2008138120A1 (fr) * 2007-05-11 2008-11-20 University Of Manitoba Système de vecteur lentiviral pseudotypé de l'hémagglutinine h5n1 du virus de la grippe aviaire pour une identification rapide d'antiviraux et une neutralisation de polypeptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GELDER C. ET AL.: "Six unrelated HLA-DR-matched adults recognize identical CD4+ T cell epitopes from influenza A hemagglutinin that are not simply peptides with high HLA-DR binding affinities", INTERNATIONAL IMMUNOLOGY, vol. 10, no. 2, 1998, pages 211 - 222, XP003002111 *
GERHARD W. ET AL.: "Identification of Eight Determinants in the Hemagglutinin Molecule of Influenza Virus A/PR/8/34 (H1N1) Which Are Recognized by Class II-RestrictedT Cells from BALB/c Mice", JOURNAL OF VIROLOGY, vol. 65, no. 1, 1991, pages 364 - 372, XP003002112 *

Also Published As

Publication number Publication date
EP2296688A2 (fr) 2011-03-23
WO2009053535A2 (fr) 2009-04-30

Similar Documents

Publication Publication Date Title
WO2010010466A3 (fr) Anticorps neutralisant anti-virus influenza a et leurs utilisations
UA115657C2 (uk) Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
WO2007089753A3 (fr) Anticorps monoclonaux qui se lient à l'hémagglutinine de la sous-classe h5 du virus de la grippe aviaire et leurs utilisations
WO2008121615A3 (fr) Formulation d'anticorps
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
MY157359A (en) Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes
CY1115932T1 (el) Σκευασμα αντισωματος
EA201100268A1 (ru) Вакцина
DE602005008996D1 (de) Radiofluorierte peptide
WO2011063235A3 (fr) Peptides, dispositifs, et procédés pour la détection d'anticorps anti-ehrlichia
WO2010002478A3 (fr) Glycopeptide et son utilisation
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
WO2008124646A3 (fr) Utilisation de protéines amyloïdes en tant qu'échafaudages pour des vaccins
WO2009035412A8 (fr) Anticorps monoclonaux spécifiques de l'hémagglutinine pour le sous-type h5 du virus de la grippe et leurs utilisations
BRPI0921717A2 (pt) composto, sequência de peptídeo isolada, composição farmacêutica, uso de um composto, anticorpo, e, método de tratamento
EA200701305A1 (ru) Иммуногенные композиции, содержащие циклические пептиды, полученные из бета-амилоидного пептида
EA201070681A1 (ru) Пептиды fviii и их применение для индукции толерантности у больных гемофилией
DE602006018424D1 (de) Peptide zum nachweis von ehrlichia ewingii antikörper
WO2011112566A3 (fr) Protéines de liaison de basigine
ZA201007635B (en) Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrieer binding domain
WO2006042149A3 (fr) Determination et reduction de l'immunoresistance a la therapie de la toxine botulinique a l'aide de peptides de la toxine botulinique de type a
DE602008005857D1 (de) Neue antimalaria-impfstoffzusammensetzungen und anwendungen davon
WO2010009856A3 (fr) Protéine de liaison d’antigène goodpasture et sa détection
WO2010133834A3 (fr) Peptide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08841911

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12739796

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008316397

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3600/DELNP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2008316397

Country of ref document: AU

Date of ref document: 20081024

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008841911

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载